Could a smaller shot still shield against yellow fever?
NCT ID NCT05374317
First seen Apr 10, 2026
Summary
This study tested whether smaller doses of the yellow fever vaccine are as safe and effective as the standard dose. Researchers gave 88 healthy adults either the full dose or a reduced dose (one-fifth or one-tenth the size). They monitored side effects and measured immune responses to see if the smaller doses could still protect against the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for YELLOW FEVER VACCINATION REACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
United States Army Medical Research Institute of Infectious Diseases
Frederick, Maryland, 21702, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Yellow fever vaccine (YF-VAX)
What this could lead to
If successful, using smaller vaccine doses could help protect more people during outbreaks or supply shortages.
What could go wrong
This is a small, early-phase study with only 88 participants, so results may not apply broadly. Lower doses might not provide enough protection.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.